The study was conducted as a result of discussions with the FDA regarding potential expedited registration pathways for oral heparin. Previous studies have repeatedly demonstrated that Emisphere’s oral heparin formulation can elevate the key parameters of anticoagulation similar to injectable heparin.
“Our data confirms that the eligen technology makes it possible to deliver heparin to the blood stream in an oral formulation,” commented Dr Robert Linhardt, professor of chemistry and chemical biology at the Rensselaer Polytechnic Institute. “The data show that heparin delivered to the blood in an oral formulation has the same molecular properties as native heparin (naturally occurring heparin) and heparin delivered by injection.”